ARTICLE | Company News
Nostrum, Institute of Microbial Technology deal
March 2, 2009 8:00 AM UTC
Nostrum received an exclusive, worldwide license from the institute to develop and commercialize Caerulomycin A, a bipyridyl immunosuppressant. Further terms were not disclosed. Caerulomycin A will b...